Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients

Public

Shared by NobleBlocks on Nov 20, 2014 • 12:00 AM UTC

Authors:

Mehdi Khellaf

Anaïs Charles-Nelson

Olivier Fain

Abstract

Key Points Tolerance of rituximab is acceptable in ITP, and with its benefit/risk ratio may remain a valid option for treating ITP in adults.